Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^*

Lemercier Jean-Luc M

2. Date of Event Requiring Statement (MM/DD/YYYY) 7/1/2017

3. Issuer Name and Ticker or Trading Symbol

Edwards Lifesciences Corp [EW]

(Last) (First) (Middle)

ONE EDWARDS WAY

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director _____ 10% Owner
___ X ___ Officer (give title below) _____ Other (specify below)
CVP, EMEA, Canada, Latin Amer /

(Street)

IRVINE, CA 92614

(City) (State) (Zip)

5. If Amendment, Date Original Filed (MM/DD/YYYY)

6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	38665.4191 ⁽¹⁾	D

*Table II - Derivative Securities Beneficially Owned ( e.g.* , puts, calls, warrants, options, convertible securities)**
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivate Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Employee Stock Option (Right to Acquire)	2/20/2015 ⁽²⁾	2/19/2021	Common Stock	5002.0000	$34.0500	D
Employee Stock Option (Right to Acquire)	5/14/2014 ⁽²⁾	5/13/2020	Common Stock	13880.0000	$35.7850	D
Employee Stock Option (Right to Acquire)	5/8/2015 ⁽²⁾	5/7/2021	Common Stock	17360.0000	$41.9400	D
Employee Stock Option (Right to Acquire)	5/9/2013 ⁽²⁾	5/8/2019	Common Stock	12560.0000	$42.7250	D
Employee Stock Option (Right to Acquire)	5/12/2012 ⁽²⁾	5/11/2018	Common Stock	16900.0000	$44.6150	D
Employee Stock Option (Right to Acquire)	5/14/2016 ⁽²⁾	5/13/2022	Common Stock	11660.0000	$65.2800	D
Employee Stock Option (Right to Acquire)	5/12/2017 ⁽²⁾	5/11/2023	Common Stock	6640.0000	$105.5900	D
Employee Stock Option (Right to Acquire)	5/11/2018 ⁽²⁾	5/10/2024	Common Stock	14400.0000	$110.2500	D
Performance Rights	5/11/2020 ⁽³⁾	⁽³⁾	Common Stock	2050.0000 ⁽³⁾	⁽³⁾	D

Explanation of Responses:
(1)	This amount includes the following four grants of restricted stock units (RSUs) made under the Edwards Lifesciences Corporation Long-Term Stock Incentive Program each of which vests 50% on the thrid anniversary of the grant date and 50% on the fourth anniversary of the grant date: (i) 2,150 RSUs on May 8, 2014, (ii) 1,380 RSUs on May 14, 2015, (iii) 850 RSUs on 5/12/2016, and (iv) 1,625 on 5/11/2017.
(2)	These options were granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program with vesting commencing one year after the grant date in four equal annual installments.
(3)	Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 11, 2017 and scheduled to vest on May 11, 2020. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award.

Remarks:
lemercierpoa.txt

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Lemercier Jean-Luc M ONE EDWARDS WAY IRVINE, CA 92614			CVP, EMEA, Canada, Latin Amer

Signatures
Ifigenia Protopappas, Attorney-in-fact		7/5/2017
^** Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.